RESUMEN

Targeting the CD20 receptor that is common to many B-cell Non-Hodgkin's Lymphoma subtypes in people, rituximab is a chimeric monoclonal antibody which has significantly improved disease-free survival rates compared with the use of cytotoxic agents alone. This study evaluated ex vivo canine B cell binding and depletion by rituximab with flow cytometric technique as possible proof of concept for treatment of canine lymphoma. Despite immunohistochemistry supporting CD20 expression, rituximab did not bind or deplete canine B cells and it is unlikely that it will be added to the armamentarium of treatment options for canine lymphoma.

Asunto(s)

Anticuerpos Monoclonales/uso terapéutico , Antineoplásicos/uso terapéutico , Enfermedades de los Perros/tratamiento farmacológico , Linfoma de Células B/veterinaria , Animales , Anticuerpos Monoclonales de Origen Murino , Perros , Citometría de Flujo/veterinaria , Linfoma de Células B/tratamiento farmacológico , Rituximab , Resultado del Tratamiento , Células Tumorales Cultivadas